| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vascular Biology |
From UMR Physiologie et Physiopathologie, Université Pierre et Marie Curie, Paris, France.
Correspondence to Michel Raymondjean, UMR Physiologie et Physiopathologie, Université Pierre et Marie Curie, Case courrier 256, Bâtiment A, 5ème étage, 7 quai St Bernard, 75252 Paris cedex 05, France. E-mail michel.raymondjean{at}snv.jussieu.fr
Objective The inflammation that occurs during the development of atherosclerosis is characterized by a massive release of sPLA2-IIA (group IIA secretory phospholipase A2) from vascular smooth muscle cells (VSMCs). We have investigated the autocrine function of sPLA2-IIA in rat aortic and human VSMCs.
Methods and Results We found that the transcription of the endogenous sPLA2-IIA gene increased by adding a cell supernatant containing human sPLA2-IIA proteins. We show that this effect was independent of the sPLA2 activity using sPLA2-IIA proteins lacking enzyme activity. Transient transfections with various sPLA2-IIA rat promoter-luciferase constructs demonstrated that the C/EBP, NK-
B, and Ets transcription factors are involved in the increase in sPLA2-IIA gene transcription. We also found the M-type sPLA2 receptor mRNA in VSMCs, and we showed that the sPLA2-luciferase reporter gene was induced by the specific agonist of the sPLA2 receptor, aminophenylmannopyranoside (APMP), and that this induction was mediated by the same transcription factor-binding sites. Finally, we used a sPLA2-IIA mutant unable to bind heparan-sulfate proteoglycans to show that the binding of wild-type sPLA2-IIA to proteoglycans is essential for the induction of an autocrine loop.
Conclusions We have thus identified new autocrine and paracrine pathways activating sPLA2-IIA gene expression in rat and human VSMCs.
A cell supernatant containing human sPLA2-IIA proteins increases the transcription of the sPLA2-IIA gene in rat and human VSMCs. This effect, independent of the sPLA2 catalytic activity, could involve a sPLA2 receptor and heparan sulfate proteoglycans binding. We thus describe a new autocrine role of sPLA2-IIA in VSMCs.
Key Words: atherosclerosis autocrine/paracrine effects type IIA sPLA2 vascular smooth muscle cells
This article has been cited by other articles:
![]() |
E. Ibeas, L. Fuentes, R. Martin, M. Hernandez, and M. L. Nieto Secreted phospholipase A2 type IIA as a mediator connecting innate and adaptive immunity: new role in atherosclerosis Cardiovasc Res, January 1, 2009; 81(1): 54 - 63. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Cho, M. R. Seon, Y. M. Lee, J. Kim, J.-K. Kim, S. G. Kim, and J. H. Y. Park 3,3'-Diindolylmethane Suppresses the Inflammatory Response to Lipopolysaccharide in Murine Macrophages J. Nutr., January 1, 2008; 138(1): 17 - 23. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ravaux, C. Denoyelle, C. Monne, I. Limon, M. Raymondjean, and K. El Hadri Inhibition of Interleukin-1{beta}-Induced Group IIA Secretory Phospholipase A2 Expression by Peroxisome Proliferator-Activated Receptors (PPARs) in Rat Vascular Smooth Muscle Cells: Cooperation between PPAR{beta} and the Proto-Oncogene BCL-6 Mol. Cell. Biol., December 1, 2007; 27(23): 8374 - 8387. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jaulmes, S. Thierry, B. Janvier, M. Raymondjean, and V. Marechal Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1{beta} FASEB J, August 1, 2006; 20(10): 1727 - 1729. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |